Robert Ford
Summary
Robert Ford is Abbott’s Executive Chairman, President & CEO, having become President and CEO in March 2020 and Chairman in December 2021.
Biography
Ford joined Abbott in 1996 through its Diabetes Care business and later held senior leadership roles across the company’s medical-device operations. Before becoming CEO, he served as President and Chief Operating Officer and as Executive Vice President of Medical Devices, overseeing Diabetes Care, Cardiovascular and Neuromodulation. He earned a bachelor’s degree from Boston College and an MBA from the University of California, Berkeley’s Haas School of Business. As CEO, Ford has led Abbott through the COVID-19 testing period, the continued expansion of the FreeStyle Libre diabetes portfolio and a broad push in cardiovascular and structural-heart products. In March 2026, Abbott completed its approximately $20.6 billion acquisition of Exact Sciences, expanding the company into cancer screening and precision-oncology diagnostics.
Notable achievements
- Led Abbott’s executive transition to an internally developed CEO, succeeding Miles White in March 2020.
- Oversaw continued development and commercialization of the FreeStyle Libre continuous-glucose-monitoring portfolio.
- Helped guide strong 2025 growth in Abbott’s heart-failure, structural-heart and electrophysiology businesses.
- Completed Abbott’s acquisition of Exact Sciences on March 23, 2026, adding products including Cologuard and Oncotype DX to Abbott’s diagnostics portfolio.
- Continued portfolio expansion through acquisitions such as Cardiovascular Systems, Inc., whose atherectomy technology complemented Abbott’s vascular-device business.
Problem areas / controversies
- Abbott’s February 2022 recall of certain Similac, Alimentum and EleCare powdered formulas led to a prolonged Sturgis, Michigan plant shutdown and contributed to severe U.S. infant-formula shortages.
- The U.S. Department of Justice opened a criminal investigation in November 2022 related to Abbott’s infant-formula manufacturing, creating an ongoing regulatory and reputational issue for the company during Ford’s tenure.
- The Exact Sciences transaction required substantial borrowing; Abbott disclosed $20 billion of acquisition-related debt financing, increasing leverage and placing added pressure on integration and future returns.
- Abbott’s COVID-19 testing revenue declined sharply as pandemic demand receded, falling from $1.6 billion in 2023 to $747 million in 2024 and $297 million in 2025.
